Abstract:
The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Abstract:
The use of an additive composition to improve the conductivity of a fuel oil. The additive composition comprises a polymeric condensation product formed by the reaction of an aliphatic aldehyde or ketone, or a reactive equivalent, with at least one ester of p-hydroxybenzoic acid.
Abstract:
The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.
Abstract:
An additive composition for a fuel oil composition and that is free of polycyclic carboxylic acids and of acid derivatives thereof comprises an additive that comprises one or more monocarboxylic acids, each having from 10 to 24 carbon atoms, or acid derivatives thereof, optionally in combination with one or both of an anti-oxidant additive and an anti-static additive.
Abstract:
The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents across in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.
Abstract:
The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Abstract:
Compounds of the formula I below are useful as additives in oleaginous compositions: ##STR1## wherein B represents an aromatic system, A represents a hydrocarbyl group, R.sup.1 and R.sup.2 are the same or are different and each independently is an aliphatic hydrocarbyl group containing 10-40 carbon atoms, provided that one of R.sup.1 and R.sup.2 may represent hydrogen; z is at least 1 and wherein the aromatic system carries at least one substituent group which is an activating group for the ring system or a derivative of an activating group.
Abstract:
Compounds of general formula (I) wherein X and Y are the same or different and are selected from the group consisting of SO.sub.3 (--), --CO--, --C(O)O(--), --R.sup.4 --C(O)O--, --NR.sup.3 C(O)--, --R.sup.4 O--, --R.sup.4 --C(O)O--, --R.sup.4 -- and --NC(O)--, R.sup.4 being --(CH.sub.2).sub.m -- where m is from 0 to 5 and R.sup.3 is defined below; X.sup.1 and Y.sup.1 are the same or different and are selected from the group consisting of (a), R.sup.1 and R.sup.2 being independently selected from the group consisting of alkyl, alkoxy alkyl or polyalkoxyalkyl groups that contain at least 10 carbon atoms in their main chain, and R.sup.3 being a hydrocarbyl group, each R.sup.3 in a compound of formula (I) being the same of different; A is, together with the carbon atoms with which it constitutes the ring structure in formula (I), an aromatic, non-aromatic, or aliphatic group, where any of such groups can be mono- or polycyclic and/or can include one or more hetero atoms selected from nitrogen, sulphur and oxygen; and Z is selected from nitro, hydroxy, alkyl, alkoxy, carboxy acid and carboxy ester, and their use as low temperature flow improvers for distillate fuels.
Abstract:
Compounds of the general formula (I) are potent sweeteners, especially 4,1',6'-tribromo-4,1',6'-trideoxygalactosucrose: ##STR1## in which R' represents a chlorine or bromine atom;R.sup.2 and R.sup.3 respectively represent a hydroxy group and a hydrogen atom or a hydrogen atom and a chlorine or bromine atom;R.sup.4 represents a chlorine or bromine atom; at least one of R', R.sup.3 and R.sup.4 representing a bromine atom.